SAM
PLX icon

Sectoral Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Sectoral Asset Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,967
Closed -$31K – 110
2018
Q4 		$31K Hold
9,967
– – ﹤0.01% 103
2018
Q3 		$72K Buy
+9,967
New +$50K 0.01% 161

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Sectoral Asset Management's PLX Position: Q1 2019 in Review

Sectoral Asset Management sold out of Protalix BioTherapeutics (PLX) in Q1 2019, closing a stake of 9,967 shares — an estimated $31K sold.

Sectoral Asset Management first reported a position in PLX in Q3 2018 and held it in 2 quarters. The position peaked at $72K in Q3 2018. 33 funds tracked by Wall St. Rank hold PLX as of Q1 2019.

  • Sectoral Asset Management reported no remaining Protalix BioTherapeutics position as of Q1 2019 after selling out during the quarter.
  • Sectoral Asset Management sold 9,967 Protalix BioTherapeutics shares in Q1 2019, an estimated $31K.
  • Sectoral Asset Management first reported a position in Protalix BioTherapeutics in Q3 2018 and held it in 2 quarters.
  • Sectoral Asset Management's Protalix BioTherapeutics position peaked at $72K in Q3 2018.
  • 33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2019.

Based on Sectoral Asset Management's 13F filing for Q1 2019, filed 14 May 2019.